Deep-Learning Serial CT Prediction of Survival in Immunotherapy-Treated Non–Small Cell Lung Cancer
JAMA Network Open · 28.01.2026 · 9 (1) · e2555759
DOI: 10.1001/jamanetworkopen.2025.55759 ↗Kurz gefasst
Fachartikel in der Zeitschrift JAMA Network Open, online erschienen am 28.01.2026. Verfasst von Chiharu Sako und 22 weiteren Autor:innen. Beteiligte Einrichtung: Onc.AI, San Carlos, California. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Tomography, X-Ray Computed, Deep Learning. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 58 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS.
Abstract (Originalsprache)
IMPORTANCE Reliable early response biomarkers for overall survival (OS) are lacking for patients receiving immune checkpoint inhibitor (ICI) therapy for advanced non–small cell lung cancer (NSCLC). Existing imaging-based measures, such as Response Evaluation Criteria in Solid Tumors (RECIST) and tumor volume change (TVC), have limited predictive value for long-term outcomes, and advanced imaging-based biomarkers may enhance decision-making in clinical practice and clinical trials. OBJECTIVE To develop and validate a fully automated deep-learning imaging-based biomarker using pretherapy and 12-week follow-up computed tomography (CT) scans. DESIGN, SETTING, AND PARTICIPANTS This prognostic study used retrospectively collected HER data from routine clinical practice (RCP) and clinical trial data from 2013 to 2023. A model using serial CT scans, Serial CT response score (Serial CTRS) was developed using a RCP discovery dataset, validated with 10 US and European institution RCP test datasets, and independently validated on a multinational clinical phase 1 trial of dostarlimab (GARNET). Participants were adults with advanced NSCLC starting ICIs in the period from 2013 to 2021 (RCP discovery), from 2013 to 2022 (RCP test), or from 2017 to 2018 (GARNET). INTERVENTIONS ICI monotherapy or combination therapy in the first-line or later-line setting. MAIN OUTCOMES AND MEASURES Cox proportional hazards regression and receiver operating characteristic-area under the curve modeled associations between Serial CTRS and OS. RESULTS The study included 1830 patients (RCP discovery, 1171 patients; RCP test, 605 patients; GARNET, 54 patients) with a median (IQR) age of 67 (19-95) years; 1000 participants were male (55%), and 830 were female (45%). Serial CTRS was associated with OS in multivariable analysis controlling for age, sex, programmed death-ligand 1 expression, histologic profile, and tumor volume (hazard ratio [HR] for 10%-point higher probability of 12-month OS, 0.74 [95% CI, 0.70-0.79] for RCP test; 0.45 [95% CI, 0.32-0.65] for GARNET). Serial CTRS outperformed RECIST and TVC in OS risk discrimination, with higher HRs distinguishing low-survival and high-survival groups in RCP test (HR, 6.19; 95% CI, 4.12-9.28) and GARNET (HR, 18.00; 95% CI, 5.40-59.97). Predictive value persisted across programmed death-ligand 1 and RECIST subgroups, including stable disease. CONCLUSIONS AND RELEVANCE In this prognostic study of patients with advanced NSCLC receiving ICI treatment, the fully automated biomarker Serial CTRS predicted OS more effectively than resource-intensive RECIST and TVC measurements using the same scans.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- Onc.AI, San Carlos, California.
- GSK, Collegeville, Pennsylvania.
- GSK, San Francsico, California.
- Department of Neuroimaging, Institute of Psychiatry, Psychology & Neuroscience, King's College London, London, United Kingdom.
- GSK, Stevenage, United Kingdom.
- Groover Consulting, Rotterdam, the Netherlands.
Förderung
- NCI NIH HHS
Zitieren
APA
Sako, C., Kurland, B. F., Schmidt, T. G., He, J., De Groot, M., Patel, A. A., Owen, D. H., Amini, A., Curti, B. D., Kelly, R. J., Page, R. D., Swalduz, A., Beregi, J. P., Chrusciel, J., Sanchez, S., Weiss, J., Liu, A., Gevaert, O., Hart, A., …, & Jordan, P. (2026). Deep-Learning Serial CT Prediction of Survival in Immunotherapy-Treated Non–Small Cell Lung Cancer. JAMA Network Open, 9(1), e2555759. https://doi.org/10.1001/jamanetworkopen.2025.55759
Vancouver
Sako C, Kurland BF, Schmidt TG, He J, De Groot M, Patel AA, et al. Deep-Learning Serial CT Prediction of Survival in Immunotherapy-Treated Non–Small Cell Lung Cancer. JAMA Network Open. 2026;9(1):e2555759. doi:10.1001/jamanetworkopen.2025.55759
BibTeX
@article{Sako2026,
author = {Sako, Chiharu and Kurland, Brenda F and Schmidt, Taly G and He, Jing and De Groot, Marius and Patel, Arpan A and Owen, Dwight H and Amini, Arya and Curti, Brendan D and Kelly, Ronan J and Page, Ray D and Swalduz, Aurelie and Beregi, Jean-Paul and Chrusciel, Jan and Sanchez, Stephane and Weiss, Jakob and Liu, An and Gevaert, Olivier and Hart, Alma and Simon, George R and Parikh, Ravi B and van der Aart, Jasper and Jordan, Petr},
title = {Deep-Learning Serial CT Prediction of Survival in Immunotherapy-Treated Non–Small Cell Lung Cancer},
journal = {JAMA Network Open},
year = {2026},
volume = {9},
number = {1},
pages = {e2555759},
doi = {10.1001/jamanetworkopen.2025.55759}
}
EUVIMED